About-cancer / kurapwa / kiriniki-kuyedzwa / chirwere / nyoro-tishu-sarcoma / kurapwa
Kurapa Kliniki Miedzo yeSoft Tissue Sarcoma
Kliniki miedzo ndeyekutsvagisa zvidzidzo zvinosanganisira vanhu. Iwo makiriniki miedzo pane ino runyorwa ndeyeye akapfava tishu sarcoma kurapwa Yese miedzo pane irondedzero inotsigirwa neNCI.
Ruzivo rweNCI rwekutanga nezve zviedzo zvemakiriniki zvinotsanangura mhando nezvikamu zvemiyedzo uye maitirwo azvo. Kliniki miedzo inotarisa nzira nyowani dzekudzivirira, kuona, kana kubata chirwere. Iwe ungangoda kufunga nezve kutora chikamu mukutora kiriniki. Taura nachiremba wako kuti akubatsire kusarudza kana imwe yakakunakira iwe.
Erdafitinib Mukurapa Varwere vane Dzokororo kana Refractory Yepamberi Solid Tumors, Isiri-Hodgkin Lymphoma, kana Histiocytic Dambudziko neFGFR Mutations (A Yevana MATCH Kurapa Kwayedza)
Ichi chikamu II Pediatric MATCH chidzidzo chekuongorora mashandiro erdafitinib ekurapa varwere vane mamota akasimba, asiri-Hodgkin lymphoma, kana histiocytic kusagadzikana kwakapararira kune dzimwe nzvimbo mumuviri uye kwakadzoka kana kusapindura kurapwa neFGFR shanduko. Erdafitinib inogona kumisa kukura kwemasero ekenza nekuvharira mamwe ma enzyme anodiwa kuti sero rikure.
Nzvimbo: 107 nzvimbo
Tazemetostat Mukurapa Varwere vane Dzokororo kana Refractory Yepamberi Solid Tumors, Isiri-Hodgkin Lymphoma, kana Histiocytic Dambudziko neEZH2, SMARCB1, kana SMARCA4 Gene Mutations (A Yevana MATCH Kurapa Kwayedza)
Ichi chikamu II Pediatric MATCH chidzidzo chekuongorora mashandiro anoita tazemetostat pakurapa varwere vane mamota akasimba, asiri-hodgkin lymphoma, kana histiocytic zvinetso zvakapararira kune dzimwe nzvimbo mumuviri uye zvakadzoka kana kusapindura kurapwa uye zvine EZH2, SMARCB1 , kana SMARCA4 kuchinja kwemajini. Tazemetostat inogona kumisa kukura kwemarara maseru nekuvharira mamwe ma enzyme anodiwa kuti sero rikure.
Nzvimbo: 109 nzvimbo
PI3K / mTOR Inhibitor LY3023414 Mukurapa Varwere vane Dzokororo kana Refractory Yakasimba Solid Tumors, Isiri-Hodgkin Lymphoma, kana Histiocytic Dambudziko neTSC kana PI3K / MTOR Mutations (A Yevana MATCH Kurapa Kwayedza)
Ichi chikamu II Pediatric MATCH kuyedza kunoongorora mashandiro anoita PI3K / mTOR inhibitor LY3023414 mukurapa varwere vane mamota akasimba, asiri-Hodgkin lymphoma, kana histiocytic kusagadzikana neTSC kana PI3K / MTOR shanduko dzakapararira kune dzimwe nzvimbo mumuviri (metastatic) uye ndadzoka (kudzokorora) kana kusapindura kurapwa (kuramba). PI3K / mTOR inhibitor LY3023414 inogona kumisa kukura kwemasero ekenza nekuvharira mamwe ma enzyme anodiwa kuti sero rikure.
Nzvimbo: 107 nzvimbo
Palbociclib Mukurapa Varwere Vakadzokororwa kana Refractory Rb Yakanaka Yakanyanya Yakasimba Solor Tumors, Isiri-Hodgkin Lymphoma, kana Histiocytic Dambudziko neKushandura Shanduko muCell Cycle Genes (A Yevana MATCH Kurapa Kwayedza)
Ichi chikamu II Pediatric MATCH chiongorori chekuongorora mashandiro anoita palbociclib mukurapa varwere vane Rb yakanaka yakasimba mamota, asiri-Hodgkin lymphoma, kana histiocytic kusagadzikana nekugadzirisa shanduko (shanduko) muma cell kutenderera majeni akapararira kune dzimwe nzvimbo mumuviri uye auya kudzoka kana kusapindura kurapwa. Palbociclib inogona kumisa kukura kwemasero ekenza nekuvharira mamwe ma enzyme anodiwa kuti sero rikure.
Nzvimbo: 97 nzvimbo
Larotrectinib Mukurapa Varwere vane Vakadzokazve kana Refractory Yakawedzera Solid Tumors, Isiri-Hodgkin Lymphoma, kana Histiocytic Dambudziko neNTRK Fusions (A Yevana MATCH Kurapa Kwayedza)
Ichi chikamu II Pediatric MATCH chiongorori chinoongorora mashandiro anoita larotrectinib mukurapa varwere vane mamota akasimba, asiri-Hodgkin lymphoma, kana kusagadzikana kwe histiocytic neNFK fusions dzakapararira kune dzimwe nzvimbo mumuviri uye dzakadzoka kana kusapindura kurapwa. Larotrectinib inogona kumisa kukura kwemasero ekenza nekuvharira mamwe ma enzyme anodiwa kuti sero rikure.
Nzvimbo: 109 nzvimbo
Cabozantinib-S-Malate Mukurapa Vechidiki Varwere neRecurrent, Refractory, kana Ichangobva Kuzivikanwa Sarcomas, Wilms Tumor, kana Mamwe maRare Tumors.
Ichi chikamu chechipiri cheyedzo yekuongorora mashandiro anoita cabozantinib-s-malate mukurapa vadiki varwere vane sarcomas, Wilms bundu, kana mamwe mamota asina kujairika akadzoka, haapindure kurapwa, kana achangobva kuongororwa. Cabozantinib-s-malate inogona kumisa kukura kwemarara maseru nekuvharira mamwe ma enzyme anodiwa kuti kukura kwetumire uye bundu reropa remidzi kukura.
Nzvimbo: 137 nzvimbo
Olaparib Mukurapa Varwere vane Vakadzokororwa kana Refractory Yepamberi Solid Tumors, Isiri-Hodgkin Lymphoma, kana Histiocytic Dambudziko nekukanganisa muDNA Kukuvara Kugadzirisa MaGenes (A Yevana MATCH Kurapa Kwayedza)
Ichi chikamu II Pediatric MATCH kuyedza kunoongorora mashandiro anoita olaparib pakurapa varwere vane mamota akasimba, asiri-Hodgkin lymphoma, kana histiocytic kusagadzikana nehurema mu deoxyribonucleic acid (DNA) yekukuvadza ekugadzirisa majeni akapararira kune dzimwe nzvimbo mumuviri (kumberi) uye vadzoka (vadzokazve) kana kusapindura kurapwa (kuramba). Olaparib inogona kumisa kukura kwemarara maseru nekuvharira mamwe ma enzymes anodiwa kuti sero kukura.
Nzvimbo: 105 nzvimbo
Vemurafenib Mukurapa Varwere vane Dzokororo kana Refractory Yakawedzera Solid Tumors, Isiri-Hodgkin Lymphoma, kana Histiocytic Dambudziko neBRAF V600 Mutations (A Yevana MATCH Kurapa Kwayedza)
Ichi chikamu II Pediatric MATCH kuyedza kunoongorora mashandiro anoita vemurafenib mukurapa varwere vane mamota akasimba, asiri-Hodgkin lymphoma, kana histiocytic kusagadzikana neBRAF V600 shanduko dzakapararira kune dzimwe nzvimbo mumuviri uye dzakadzoka kana kusapindura kurapwa. Vemurafenib inogona kumisa kukura kwemarara maseru nekuvhara mamwe ma enzymes anodiwa kuti sero kukura.
Nzvimbo: 106 nzvimbo
Atezolizumab Mukurapa Varwere neNewly Diagnosed uye Metastatic Alveolar Soft Chikamu Sarcoma Icho Chisingakwanise Kubviswa nekuvhiya.
Ichi chikamu chechipiri cheyedzo yekuongorora kuti atezolizumab inoshanda sei pakurapa varwere vane alveolar nyoro chikamu sarcoma iyo isina kurapwa, yapararira kubva kwayakatanga ichienda kune dzimwe nzvimbo mumuviri uye haigone kubviswa nekuvhiyiwa. Immunotherapy ine monoclonal antibodies, senge atezolizumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira.
Nzvimbo: 39 nzvimbo
Nivolumab neIpilimumab Mukurapa Varwere vaneHIV Yakabatana Yakadzokororwa kana Refractory Classical Hodgkin Lymphoma kana Solid Tumors Iyo Ine Metastatic kana Haigone Kubviswa neKuvhiya
Ichi chikamu I muyedzo unoongorora mhedzisiro uye yakanakisa dosi yeiyo nivolumab painopihwa neipilimumab mukurapa varwere vane hutachiona hwehutachiona hwehutachiona (HIV) inosanganisirwa yechinyakare Hodgkin lymphoma yakadzoka mushure menguva yekuvandudza kana kusapindura kurapwa, kana mamota akasimba ayo yakapararira kune dzimwe nzvimbo mumuviri kana kuti haigone kubviswa nekuvhiya. Immunotherapy ine monoclonal antibodies, senge ipilimumab uye nivolumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Ipilimumab chirwere chinorwisa mamorekuru anonzi cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 inodzora chikamu chemuviri wako nekudzivirira iyo pasi. Nivolumab rudzi rweantibody iyo yakanangana neyakagadzirirwa munhu kufa kwesero 1 (PD-1), puroteni ine chekuita nekuparadzwa kwema immune immune. Kupa ipilimumab ne nivolumab kunogona kushanda zvirinani pakurapa varwere vane hutachiwana hweHIV hwakabatana hwechinyakare Hodgkin lymphoma kana mamota akasimba achienzaniswa neipilimumab ine nivolumab chete.
Nzvimbo: 28 nzvimbo
MDM2 Inhibitor AMG-232 uye Radiation Therapy Mukurapa Varwere vane Nyoro Tissue Sarcoma
Ichi chikamu Ib kuyedza inoongorora iyo mhedzisiro ye MDM2 inhibitor AMG-232 uye radiation kurapwa pakurapa varwere vane nyoro tishu sarcoma. MDM2 inhibitor AMG-232 inogona kumisa kukura kwemasero ekenza nekuvharira mamwe ma enzyme anodiwa kuti sero rikure. Kupa MDM2 inhibitor AMG-232 uye kurapwa nemwaranzi usati wavhiyiwa kunogona kuita kuti bundu rive diki uye kudzikamisa huwandu hweturuvara hunoda kubviswa.
Nzvimbo: 27 nzvimbo
Nivolumab ane kana asina Ipilimumab Mukurapa Vechidiki Varwere neRecurrent kana Refractory Solid Tumors kana Sarcomas
Ichi chikamu I / II kuyedza kunoongorora iyo mhedzisiro uye yakanakisa dosi ye nivolumab painopihwa pamwe kana isina ipilimumab kuti vaone mashandiro avanoshanda pakurapa vadiki vadiki vane mamota akasimba kana sarcomas akadzoka (achidzokororazve) kana asinga pindure kurapwa ( zvinopesana). Immunotherapy ine monoclonal antibodies, senge nivolumab uye ipilimumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Izvo hazvisati zvazivikanwa kana nivolumab inoshanda zvirinani iri yega kana iine ipilimumab mukurapa varwere vanodzokororazve kana kusagadzikana yakasimba mamota kana sarcomas.
Nzvimbo: 24 nzvimbo
Selinexor muAdvanced Liposarcoma
Iyi yakasarudzika, multicenter, yakapofomara-yakapetwa, inochengetedzwa ne placebo, Phase 2-3 kudzidza kwevarwere vanoonekwa vane epamberi isingagadzirisike dedifferentiated liposarcoma. Vanoda kusvika 279 varwere vese vanozoitwa randomized kudzidza kurapwa (selinexor kana placebo).
Nzvimbo: 21 nzvimbo
(VOYAGER) Kudzidza kweAvapritinib vs Regorafenib mune Varwere Vane Nharaunda Yepamberi Isinga tsanangurike kana Metastatic GIST
Ichi chakavhurika-chirevo, chakasarudzika, Chikamu chechitatu kudzidza mune varwere vane epamberi nzvimbo isingachinjike kana metastatic GIST (advanced GIST) yeavapritinib (inozivikanwawo seBLU-285) maringe regorafenib mune varwere vakamborapwa ne imatinib uye 1 kana 2 mamwe maTKI.
Nzvimbo: 14 nzvimbo
Chikamu 1 Chidzidzo cheEZH2 Inhibitor Tazemetostat muVana Vechikoro Vanodzokororwa kana Kufuridzira INI1-Negative Tumors kana Synovial Sarcoma
Ichi chiNhanho I, yakavhurika-chitaridzi, kuwedzera kwedosi uye kuwedzera kuwedzerwa kudzidza neBID yemuromo tazemetostat. Zvidzidzo zvichavhenekwa kuti zvikwanise mukati memazuva gumi nemana kubva padanho rekutanga rakarongwa re tazemetostat. Kurapa kutenderera kuchave mazuva makumi maviri nemasere. Kuongorora kwemhinduro kunozoongororwa mushure memavhiki masere ekurapwa uye zvichizotevera mavhiki masere ese uchiri kudzidza. Chidzidzo chine zvikamu zviviri: Kuwedzera kweDose uye Kuwedzera kweDose. Dose kukwira kwezvidzidzo zvine zvinotevera zvakadzokororwa / zvinokanganisa malignancies: - Rhabdoid tumors: - Atypical teratoid rhabdoid bundu (ATRT) - Malignant rhabdoid bundu (MRT) - Rhabdoid bundu reitsvo (RTK) - Akasarudzwa mamota ane rhabdoid maficha - INI1-asina matumbo :
Nzvimbo: 14 nzvimbo
Adavosertib uye Irinotecan Hydrochloride Mukurapa Vechidiki Varwere vane Dzokororo kana Refractory Solid Tumors.
Ichi chikamu I / II kuyedza kunoongorora iyo mhedzisiro uye yakanyanya dhosi yeadavosertib uye irinotecan hydrochloride pakurapa vadiki vadiki vane mamota akasimba akadzoka (adzokazve) kana asina kupindura kune akajairwa kurapa (anokanganisa) Adavosertib uye irinotecan hydrochloride inogona kumisa kukura kwemarara maseru nekuvharira mamwe ma enzymes anodiwa kuti sero rikure.
Nzvimbo: 22 nzvimbo
Chikamu cheChitatu III Kutongwa kweAnlotinib muMetastatic kana Yepamberi Alveolar Soft Chikamu Sarcoma, Leiomyosarcoma uye Synovial Sarcoma
Ichi chidzidzo chinoongorora kuchengetedzeka uye kushanda kwe AL3818 (anlotinib) hydrochloride pakurapa metastatic kana epamberi alveolar nyoro chikamu sarcoma (ASPS), leiomyosarcoma (LMS), uye synovial sarcoma (SS). Vese vatori vechikamu vane ASPS vanogashira yakavhurika-chitaridzi AL3818. Mune vatori vechikamu neLMS kana SS, AL3818 ichaenzaniswa neIV dacarbazine. Zvikamu zviviri kubva muzvitatu zvevatori vechikamu vanogashira AL3818, chetatu chevatori vechikamu vanogashira IV dacarbazine.
Nzvimbo: 14 nzvimbo
Nab-Paclitaxel uye Gemcitabine Hydrochloride Mukurapa Vechidiki kana Vechidiki Vakuru neRecurrent or Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, kana Soft Tissue Sarcoma
Ichi chikamu chechipiri cheyedzo yekuongorora kuti nab-paclitaxel uye gemcitabine hydrochloride inoshanda sei pakurapa vechidiki kana vechidiki vechidiki vane osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, kana soft tishu sarcoma yakadzoka kana isingapindure kurapwa. Zvinodhaka zvinoshandiswa mukemotherapy, senge nab-paclitaxel uye gemcitabine hydrochloride, zvinoshanda munzira dzakasiyana kumisa kukura kwemarara maseru, kungave nekuuraya iwo maseru, nekuamisa iwo kubva pakupatsanura, kana nekuamisa iwo pakupararira.
Nzvimbo: 18 nzvimbo
Olaparib uye Temozolomide Mukurapa Varwere vane Yepamberi, Metastatic, kana Isingaonekwe Uterine Leiomyosarcoma
Ichi chikamu II chidzidzo chekuyedza olaparib uye temozolomide mukurapa varwere vane uterine leiomyosarcoma (LMS) iyo yakapararira kune dzimwe nzvimbo mumuviri (yakakwira kana metastatic) kana isingakwanise kubviswa nekuvhiya (kusingadzoreki). Olaparib inogona kumisa kukura kwemarara maseru nekuvharira mamwe ma enzymes anodiwa kuti sero kukura. Zvinodhaka zvinoshandiswa mukemotherapy, senge temozolomide, zvinoshanda munzira dzakasiyana kumisa kukura kwemarara maseru, kungave nekuuraya maseru, nekuamisa iwo kubva pakupatsanuka, kana nekuamisa iwo pakupararira. Kupa olaparib uye temozolomide kunogona kushanda zvirinani pane kupa chero mushonga wega pakurapa varwere vane LMS.
Nzvimbo: 12 nzvimbo
Kudzivirirwa, Kushivirira uye PK Kudzidza kweDCC-2618 mune Varwere Vane Yakanyanya Malignancies
Ichi chikamu cheChikamu 1, yakavhurika-chitaridzi, yekutanga-mu-munhu (FIH) yedosi-yekuwedzera kudzidza yakagadzirirwa kuongorora kuchengetedzeka, kushivirira, pharmacokinetics (PK), pharmacodynamics (PD) uye yekutanga antitumor chiitiko cheDCC-2618, inotungamirwa nemuromo (PO), mune varwere vakuru vane malignancies epamberi. Chidzidzo ichi chine zvikamu zviviri, chikamu chekuwedzera kwedosi uye chikamu chekuwedzera.
Nzvimbo: 12 nzvimbo
Nelfinavir Mesylate Mukurapa Varwere neKaposi Sarcoma
Ichi chirongwa chekuchaira chikamu chechipiri chekuyedza mashandiro anoita nelfinavir mesylate mukurapa varwere veKaposi sarcoma. Nelfinavir mesylate inogona kumisa kukura kwemarara maseru nekuvharira mamwe ma enzyme anodiwa kukura kwesero.
Nzvimbo: 11 nzvimbo
sEphB4-HSA Mukurapa Varwere neKaposi Sarcoma
Ichi chikamu II chekuyedza chinodzokorora recombinant EphB4-HSA fusion protein (sEphB4-HSA) pakurapa varwere vane Kaposi sarcoma. Recombinant EphB4-HSA fusion protein inogona kutadzisa kukura kwemidziyo yeropa inopa ropa kukenza, uye inogona zvakare kudzivirira cancer maseru kubva mukukura.
Nzvimbo: 10 nzvimbo
Chikamu chechipiri, Multicenter Kudzidza kweEZH2 Inhibitor Tazemetostat muVakuru Vateereri NeII1-Negative Tumors kana Yakadzoswazve / Refractory Synovial Sarcoma
Ichi chikamu chechipiri II, multicenter, yakavhurika-label, ruoko rumwe chete, 2-nhanho yekudzidza tazemetostat 800 mg BID inotungamirwa nemuromo mukuenderera kwemazuva makumi maviri nemasere Kuongororwa kwezvidzidzo kuona kukodzera kwechidzidzo ichi kuchaitwa mukati memazuva makumi maviri nemana kubva padanho rekutanga rakarongwa re tazemetostat. Zvidzidzo zvinokodzera zvinonyoreswa kuita chimwe chezvidhakwa zvishanu zvichibva pachironda mhando: - Cohort 1 (Yakavharirwa kunyoreswa): MRT, RTK, ATRT, kana mamota akasarudzwa ane maficha erabhdoid, kusanganisira diki cell carcinoma yeiyo ovary hypercalcemic mhando [SCCOHT], zvakare inozivikanwa seyakashata rhaboid bundu reovary [MRTO] - Cohort 2 (Yakavharirwa kunyoreswa): Yakadzoreredzwa kana kusagadzikana synovial sarcoma ine SS18-SSX rearrangement - Cohort 3 (Yakavharirwa kunyoreswa): Dzimwe INI1 isina kunaka mamota kana chero bundu rakasimba rine EZH2 kuwana kwekushanda (GOF) shanduko, kusanganisira:
Nzvimbo: 12 nzvimbo
SARC024: Blanket Protocol yekudzidza Oral Regorafenib mune Varwere vane Sarudzo Sarcoma Subtypes
Kunyangwe regorafenib yakagamuchirwa kuti ishandiswe mune varwere vane GIS inofambira mberi kunyangwe imatinib uye / kana sunitinib pahwaro hwechikamu chechipiri nedata rechitatu, haina kuongororwa nenzira yakarongeka mune varwere vane mamwe marudzi esarcoma. Tichifunga nezve chiitiko cheSorafenib, sunitinib uye pazopanib mune zvinyoro zvinyama sarcomas, uye humbowo hwechiitiko chesorafenib muosteogenic sarcoma uye pamwe Ewing / Ewing-sarcoma, kune muenzaniso wekutarisa maSMOKI (madiki mamorekuru emuromo kinase inhibitors) senge regorafenib mune sarcomas zvimwe kunze kweGIST. Izvo zvinozivikanwawo kuti maSMOKI (madiki mamorekuru emuromo kinase inhibitors) senge regorafenib, sorafenib, pazopanib, uye sunitinib ane mapapiro anopindirana eaninase ayo anotadziswa panguva imwe chete. Kunyange zvisina kuenzana,
Nzvimbo: 10 nzvimbo
Kuchengetedza, Kushivirira uye Pharmacokinetics yeAn anti-PD-1 Monoclonal Antibody mune Zvidzidzo zvine Advanced Malignancies
Chinangwa chekutanga ndechekuongorora kuchengetedzeka uye kushivirira kweToripalimab muzvidzidzo zvine malignancies akasiyana siyana uye kuongorora iyo yakakurudzirwa Phase 2 dose. Zvinangwa zvechipiri ndezvekuti: 1) tsanangura iyo pharmacokinetic (PK) nhoroondo yeToripalimab, 2) kuongorora antitumor chiitiko cheToripalimab; 3) sarudza iyo immunogenicity yeToripalimab; 4) ongorora kupona kwese. Zvinangwa zvekutsvaga ndezvekuti: 1) ongorora biomarkers anogona kuenderana nezviitiko zveToripalimab, 2) ongorora macompodyodynamic mhedzisiro yeToripalimab pane yayo inotarisirwa receptor, yakarongedzwa sero kufa 1 (PD-1), pamwe nemhedzisiro pane immune system. 3) ongorora iko kushandiswa kwePD-L1 & yekuwedzera mamaki ekuongorora se biomarkers ayo anogona kubatsira mukusarudza kwakakodzera zvidzidzo zveTAB001 kurapa,
Nzvimbo: 9 nzvimbo
